LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Company management will present at two upcoming scientific conferences.
Presentation at the 3rd Annual Ophthalmic Drugs Conference
A presentation will be delivered by Aniz Girach, MD, Chief Medical Officer of ProQR, during the 3rd Annual Ophthalmic Drugs Conference to be held November 19-20, 2019 in London.
|Presentation Title:||Antisense Oligonucleotides for Inherited Retinal Diseases|
|Presentation Time:||Wednesday, November 20 at 1:20-2:00 p.m. GMT|
Presentation at the 1st RNA Editing Summit
During the 1st RNA Editing Summit to be held on November 19-20, 2019 in Boston, MA, a presentation will be delivered by David Rodman, MD, Executive Vice President of Research and Development of ProQR.
|Presentation Title:||Translating RNA Editing to Our Clinical Development Pipelines|
|Presentation Time:||Wednesday, November 20 at 9:40-10:10 a.m. EST|
This presentation will highlight ProQR’s proprietary Axiomer® platform, a fully owned and in house developed RNA platform with broad applicability. ProQR is accelerating this platform for precision medicine in the retina with oligonucleotide therapeutics.
About Axiomer® platform technology
ProQR is pioneering a next-generation RNA technology called Axiomer®, which could potentially yield a new class of medicines for genetic diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells. The Axiomer® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G).
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such statements include those relating to our participation at the 3rd Annual Ophthalmic Drugs Conference and 1st RNA Editing Summit. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
LifeSci Public Relations
T: +1 646 876 4933